Latest Us Market News

Ionic Rare Earths’ subsidiary Ionic Technologies has led a pioneering UK project demonstrating a fully circular supply chain for electric vehicle magnets using 100% recycled rare earth oxides, achieving performance parity with primary materials and advancing UK critical minerals goals.

Amaero Ltd has sent out its Scheme Booklet for the upcoming June 5, 2026 meetings where shareholders will vote on the company’s re-domiciliation to the US and approve new incentive options.

Neuren Pharmaceuticals saw a 20% jump in Q1 2026 DAYBUE net sales to US$101 million, with royalties up 23%. The Japan trofinetide trial has been fast-tracked, and the new powder formulation DAYBUE STIX gains early traction.

Zip Co’s April update highlights robust US and ANZ market expansion, with total transaction volume surging and credit losses forecast below 1.75%. The company reconfirms FY26 guidance, underpinned by AI-driven underwriting and new subscription offerings.

Acusensus Limited maintains its FY26 revenue and EBITDA guidance while advancing multiple enforcement programs across the US, UK, New Zealand, and Australia, underpinned by new product developments and international growth.

Noxopharm is gearing up for a pivotal pre-IND meeting with the US FDA, enlisting global CRO Novotech to sharpen its regulatory approach for SOF-SKN, a drug targeting autoimmune skin diseases.

Nova Eye Medical has smashed its US sales record in April 2026, prompting an upgrade to its FY26 sales guidance and marking a milestone with positive operational EBITDA.

Entropy Neurodynamics has bolstered its intellectual property portfolio with a new US provisional patent application for TRP-8803, following compelling Phase 2a data showing a 75% response rate in treatment-resistant IBS patients.

ImpediMed has secured A$15.2 million through a two-tranche placement and share purchase plan, alongside A$5 million in cost reductions, aiming for operating cashflow breakeven by H2 FY28.

The Hydration Pharmaceuticals Company Limited (ASX: HPC) has had its trading suspension lifted as of 4 May 2026, following the lodgement of its delayed Annual Report revealing a $2.86 million net loss.

Imricor Medical Systems has secured A$60 million through a placement to fund its US commercial rollout, regulatory approvals, and clinical programs, boosting its cash reserves to nearly A$103 million.

The Smart US 500 ETF reported a near-billion-dollar fund size with a 5-year average annual return of 14.14% after fees and tax, maintaining a high-risk profile and low management fees of 0.34%.